Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (EXC 306, EXC 2167, DGRK 1473, GRK 1727)
Received: 21 February 2019
Accepted: 13 August 2019
First Online: 10 September 2019
: R.J.L. has received research funding from Miltenyi Biotec, Biogen, Biotest, Almirall, True North Therapeutics, UCB Pharma, ArgenX, TxCell, Topadur, Incyte and Admirx and fees for consulting or speaking from ArgenX, Immunogenetics, Novartis and Lilly. All other authors declare no competing interests.